ORIGINAL ARTICLE |
|
Year : 2013 | Volume
: 38
| Issue : 2 | Page : 80-83 |
|
Smac/DIABLO gene expression in acute myeloid leukemia patients
Ghada A. Suliman1, Maaly M. Mabrouk1, Enaam S. Rabee1, Amr Gawaly2
1 Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt 2 Department of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt
Correspondence Address:
Maaly M. Mabrouk MD, Department of Clinical Pathology, Faculty of Medicine, Tanta University, 31527 Tanta Egypt
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.7123/01.EJH.0000428063.29317.e1
|
|
Background
Smac/DIABLO enhances apoptosis by antagonizing the inhibitors of apoptotic proteins. The expression of Smac/DIABLO in different cancers has been reported. The study aimed to evaluate Smac/DIABLO gene expression in patients with acute myeloid leukemia (AML) and also to determine its relation to the clinical outcome and survival of these patients.
Materials and methods
Smac/DIABLO gene expression was studied using real-time PCR in bone marrow samples from 70 newly diagnosed AML patients.
Results
The Smac/DIABLO gene was expressed in 88.5% of AML patients. A total of 32 patients (51.6%) with positive Smac/DIABLO expression responded to treatment, and the remaining 30 patients (48.4%) were treatment resistant. Smac/DIABLO expression was associated with decreased lactate dehydrogenase levels and increased disease-free survival (P=0.01 and P<0.001, respectively). The expression was associated with an increase in the survival rate (P<0.05).
Conclusion
There was an increase of Smac/DIABLO expression in AML patients, and this was associated with the treatment response, increased disease-free survival, and better overall survival. |
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|